Literature DB >> 15280570

Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project).

E Hallert1, M Husberg, D Jonsson, T Skogh.   

Abstract

OBJECTIVE: To calculate direct and indirect costs in early rheumatoid arthritis (RA) and to characterize patients generating high and low costs respectively.
METHODS: Two hundred and ninety-seven patients with recent-onset (< or = 12 months) RA were recruited. Clinical/laboratory data and 'health assessment questionnaire' (HAQ) were registered at inclusion and after 3, 6 and 12 months. After 6 and 12 months, the patients completed a questionnaire concerning health-care utilization and days lost from work. A cut-off point for direct costs was set at 34,000 Swedish kronor (euro3675) defining one-third of the patients as a high-cost group and two-thirds as low-cost group. Indirect costs were calculated for patients aged <65 yr.
RESULTS: Two hundred and eleven patients completed the HAQ on both occasions. Indirect costs exceeded direct costs by a factor of 2.3. Sixty three per cent experienced work disability during the first year and were identified as the 'high-indirect-cost group'. Indirect costs accounted for >70% of total costs. Direct costs included ambulatory health care (76%), hospitalization (12%) and medication (9%). Men aged > or = 65 yr had low costs compared with younger men and women of all ages. In multiple logistic regression tests, HAQ, high levels of IgM rheumatoid factor (IgM RF) and poor hand function increased the odds of entering the high-direct-cost group, and poor hand function and pain increased the odds of entering the high-indirect-cost group.
CONCLUSIONS: Substantial costs were incurred during the first year after diagnosis of early RA, mainly due to work disability. Indirect costs were two to three times higher than direct costs. High levels of IgM RF, high HAQ score, poor hand function and pain increased the odds of entering high-cost groups.

Entities:  

Mesh:

Year:  2004        PMID: 15280570     DOI: 10.1093/rheumatology/keh324

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  13 in total

Review 1.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial.

Authors:  K Puolakka; H Kautiainen; M Pekurinen; T Möttönen; P Hannonen; M Korpela; M Hakala; M Arkela-Kautiainen; R Luukkainen; M Leirisalo-Repo
Journal:  Ann Rheum Dis       Date:  2005-11-16       Impact factor: 19.103

3.  The impact of rheumatoid arthritis and biologics on employers and payers.

Authors:  Paresh Chaudhari
Journal:  Biotechnol Healthc       Date:  2008-07

4.  Factors influencing sick leave episodes in Mexican workers with rheumatoid arthritis and its impact on working days lost.

Authors:  Laura Gonzalez-Lopez; Jaime Morales-Romero; M Luisa Vazquez-Villegas; Rebeca Villa-Manzano; Alberto D Rocha-Muñoz; Azael Barragan-Enriquez; Alfredo Celis; Carlos E Cabrera-Pivaral; Jorge I Gamez-Nava
Journal:  Rheumatol Int       Date:  2012-03-31       Impact factor: 2.631

5.  Sick leave as a predictor of job loss in patients with chronic arthritis.

Authors:  Petronella D M de Buck; Geertruida H de Bock; Frank van Dijk; Wilbert B van den Hout; Jan P Vandenbroucke; Theodora P M Vliet Vlieland
Journal:  Int Arch Occup Environ Health       Date:  2006-05-20       Impact factor: 3.015

Review 6.  Health economics: implications for novel antirheumatic therapies.

Authors:  A Kavanaugh
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

7.  Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany.

Authors:  D Huscher; S Merkesdal; K Thiele; H Zeidler; M Schneider; A Zink
Journal:  Ann Rheum Dis       Date:  2006-03-15       Impact factor: 19.103

8.  Work disability among two cohorts of women with recent-onset rheumatoid arthritis: a survival analysis.

Authors:  S Reisine; J Fifield; S Walsh; D Dauser
Journal:  Arthritis Rheum       Date:  2007-04-15

9.  Socioeconomic and employment status of patients with rheumatoid arthritis in Korea.

Authors:  Jeong-Mi Kwon; Jinnie Rhee; Hyemin Ku; Eui-Kyung Lee
Journal:  Epidemiol Health       Date:  2012-05-07

10.  Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group.

Authors:  M T Halpern; M A Cifaldi; T K Kvien
Journal:  Ann Rheum Dis       Date:  2008-10-01       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.